Non-small cell lung cancers (NSCLCs) are heterogeneous cancers. In 2004, the
identification of epidermal growth factor receptor (EGFR) somatic mutations provided the first …

Targeted therapies have changed the landscape of treatments for non-small cell lung cancer
(NSCLC). Specific targeted therapies have been approved for NSCLC patients harboring …

Background Pruritus has been anecdotally described in association with targeted cancer
therapies. The risk of pruritus has not been systematically ascertained. Objective A …

Increased tumor uptake of 18F-fluorodeoxyglucose (FDG) measured by positron emission
tomography (PET) reflects glucose metabolism and proliferative activity of tumor cells. We …

Purpose Exon 19 deletion and exon 21 L858R mutation were the most common epidermal
growth factor receptor (EGFR) mutations. We examined the clinical impact of these two …

Background. For non-small cell lung cancer (NSCLC) patients with epidermal growth factor
receptor (EGFR) mutations, first-line gefitinib produced a longer progression-free survival …

Purpose Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have
proven efficacy in advanced non–small-cell lung cancer (NSCLC). Their role in early-stage …

The high frequency of epidermal growth factor receptor (EGFR) mutations in tyrosine kinase
inhibitor‐responsive non‐small‐cell lung cancer (NSCLC) cases is now well established …

Globally, lung cancer is the leading cause of cancer-related death. The majority of non-small
cell lung cancer (NSCLC) tumours express epidermal growth factor receptor (EGFR), which …

Clinical experience with the EGFR-TKI gefitinib in Asian patients with NSCLC will be
reviewed, both in patients who have previously failed chemotherapy and in the first-line …